Enke Bashllari is a trained neuroscientist who left academic research at Columbia University to become a venture capital investor, specifically to help translate brain and biology science into real-world medical advances rather than taking the typical finance or consulting path into VC. She focuses on investing in neurotech and AI-driven biology platforms during what she sees as a "now is possible" window created by recent advances at the intersection of hardware, software, and biology.

• Deep conviction in the future of neurotechnology and brain-computer interfaces to solve clinical needs. Frequently highlights the potential of treating brain diseases through targeted electrical signals rather than just biological drugs, exemplified by sustained support for companies like Paradromics and close attention to FDA guidance in the space.
• Championing digital medicine and the integration of advanced hardware into clinical care. Shows specific enthusiasm for tools that improve surgical outcomes, such as using augmented reality to provide surgeons with better anatomical details during procedures, as seen with the investment in Medivis.
• Practical advice regarding healthtech team composition. Specifically warns that startups claiming to solve complex medical disorders must have a medical doctor on the founding team or as an active advisor to demonstrate credibility in care delivery.
• Focus on operational discipline and deal structure. Has noted that a misaligned cap table from the start is a frequent reason for passing on otherwise promising companies and advises founders to focus on profitability and margins rather than trying to manufacture FOMO with investors.
• Support for next-generation primary care and women's health models. celebrates milestones for hybrid clinic startups that combine traditional medicine with nutrition and lifestyle management, frequently cheering on portfolio companies like Tia and Parsley Health.
• A hands-on approach to deep tech investing where scientific expertise is required. Actively looks to support founders beyond capital, such as offering to help connect deep tech ventures with Key Opinion Leaders and scientific guidance to help them execute.